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Abstract
Background/Aims: Lung carcinoids are uncommon neuroendocrine tumours. Molecular 
features of lung carcinoids have been poorly defined. microRNAs (miRNAs) are potent gene 
expression regulators with important roles in cancer development and progression. However, 
little is known on the role of miRNAs in the pathogenesis of lung carcinoids. Our goals were 
to identify commonly deregulated miRNAs in a rare case of lung carcinoid of typical histology 
with metastasis, as well as map miRNA target genes in pathways potentially associated 
with disease development and progression. Methods: miRNA expression profiles were 
assessed using the TaqMan Low Density Arrays, which is a platform including 384 miRNAs. 
miRNA profiles were generated in the tumor and its corresponding lymph node metastasis, 
compared to reference normal lung tissues. Furthermore, miRNA expression was validated 
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in a separate, publicly available external dataset (n=19 typical lung carcinoids; 2/19 were 
metastatic tumors, compared to six normal lung tissues, GSE77380). Following this analysis, 
computational tools were applied for data interpretation. miRTarBase was used to determine 
miRNA-target genes, followed by ToppGene Suite analysis to identify pathways and biological 
functions. In addition, the expression of genes targeted by miRNAs was validated in a second, 
separate external dataset (n=13 tumour samples, GSE35679). GEO2R data analysis tool was 
used in both validation analyses (miRNAs and genes). Results: We identified 15 commonly 
significantly downregulated miRNAs (fold change, FC≥2 and p<0.05) in the tumour and its 
paired metastasis, with further decreasing levels in the metastatic lesion. Downregulation of 
miR-126-3p and miR-146b-5p was validated in the external dataset GSE77380. In addition, 
SOX2 and TCF4 genes, targeted by miR-126-3p, were consistently overexpressed in a subset 
of six typical lung carcinoids from the external dataset GSE35679. Pathways analysis showed 
that miRNAs miR-126-3p and miR-146b-5p target genes with a role in the regulation of 
adaptive immune response. Conclusion: Our results contribute to the identification of miRNA 
expression changes in a typical lung carcinoid and its corresponding lymph node metastasis. 
Down-regulated levels of miR-126-3p and miR-146b-5p and target gene over-expression 
could play a role in the progression of this case of primary typical lung carcinoid to regional 
metastasis. Identified miRNAs and target genes are potential candidates for validation in a 
larger number of cases.
Introduction
Lung neuroendocrine tumours comprise approximately 25% of lung cancer cases; 
among these, typical lung carcinoids are low-grade neuroendocrine lesions accounting for 
only approximately 2% of cases, with atypical carcinoids representing about 0.2% of cases [1]. 
Typical carcinoids are most common in younger patients (~45 years old), not usually related 
to smoking and infrequently associated with metastasis at diagnosis, with a 5-year overall 
survival of >80%. Diagnosis of typical lung carcinoids is based on histological examination 
and mitotic counting lower than two mitoses per 2 mm², without necrosis. Disease staging 
follows the TNM categorization, and surgery remains the standard treatment because of the 
high failure rates of chemo- or radiotherapy [2]. Patients eligible for surgical resection have 
better long-term survival, and the presence of metastatic disease is associated with shorter 
disease-specific survival [3]. The presence of regional lymph node metastasis is reported in 
approximately 9% of typical lung carcinoids [4]. Typical lung carcinoids can metastasize to 
distant organs, mainly the liver and bones, and atypical carcinoids may spread to multiple 
distant organs, including the liver, bones, brain, spleen, adrenal glands, and soft tissues [5]. 
Furthermore, disease recurrence has been observed even decades after primary tumour 
resection [6].
The histopathological features of lung carcinoids, such as well-differentiated cells, 
organoid growth pattern, and absence of necrosis [2], are useful for their classification; 
however, the molecular alterations associated with disease development and progression 
are poorly understood. Lung carcinoids have fewer genetic changes than other tumour 
types, and when these changes occur, the genes involved are more frequently related to 
epigenetic mechanisms, cellular metabolism, and DNA damage response [7, 8]. In addition, 
neuroendocrine lung tumours have a different mutational profile compared to non-small cell 
lung cancer [9]. These data suggest that there are different regulatory mechanisms associated 
with tumorigenesis and progression of lung carcinoids. However, such mechanisms are 
widely unknown.
microRNAs (miRNAs) are small non-coding RNAs that regulate post-transcriptional 
gene expression related to several cellular processes, playing an important role in disease, 
including benign and malignant tumours [10]. The role of miRNAs in neuroendocrine 
tumours has been investigated in a few studies [11–14]. Mairinger et al. [11] assessed 
miRNA expression in pulmonary neuroendocrine tumours, including typical and atypical 
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carcinoids, large cell neuroendocrine and small cell lung cancer. Interestingly, these authors 
reported decreasing expression levels of miR-29a, miR-29b, and miR-29c associated with 
more aggressive tumour subtypes, from lung carcinoids to large cell carcinoma and small 
cell lung cancer. Deng et al. [12] reported three miRNA target genes (CREB5, PTPRB, and 
COL4A3) as having significantly lower expression levels in carcinoid tumours compared to 
normal lung tissues; however the authors state that further studies are needed to elucidate 
the biological significance of these genes associated with lung carcinoid tumorigenesis. Rappa 
et al. [13] identified distinct miRNA expression profiles in the different subtypes of lung 
carcinoid tumours; they reported five miRNAs (miR-129-5p, miR-409-3p, miR-409-5p, miR-
185, and miR-497) significantly overexpressed in typical compared to atypical carcinoids, 
and three underexpressed miRNAs (miR-409-3p, miR-409-5p, and miR-431-5p) in typical 
and atypical cases presenting with lymph node metastasis. Finally, Yoshimoto et al. [14] 
performed a comparative study including pulmonary carcinoids, small cell lung cancer, and 
gastrointestinal neuroendocrine tumours and reported specific miRNA expression profiles 
suggestive of a common origin for lung and gastrointestinal neuroendocrine cancers. 
Interestingly, miRNA expression patterns in lung carcinoids were distinct from small cell 
lung cancers, reflecting their differences in histogenesis.
Here, we contribute with original miRNA expression data in a rare case of typical lung 
carcinoid with lymph node metastasis, as well as miRNA and gene expression data validation 
in independent, publicly available patient datasets. Furthermore, we provide data on the 
analysis of pathways and biological functions of genes targeted by miRNAs. By investigating 
miRNA changes common to the primary tumour and the metastatic lesion from the same 
patient, we may be able to identify miRNAs potentially associated with disease progression.
Materials and Methods
Patient samples
A typical lung carcinoid tumour, and its paired lymph node metastasis, were obtained from surgical 
resection in a female patient, 38-year-old at diagnosis, non-smoker, and with no family history of cancer. 
Disease diagnosis confirmed a locally invasive typical carcinoid tumour (tumour size 4 x 2.5 x 2.5 cm), 
T2aN1M0 (pathological stage IIB), according to the American Joint Committee on Cancer staging system 
(AJCC, 8th edition). Formalin-fixed, paraffin-embedded (FFPE) tissues were obtained from the Pathology 
Department, Botucatu Clinical Hospital, FMB, UNESP, São Paulo, Brazil. Two formalin-fixed, paraffin 
embedded (FFPE) tissue blocks were obtained from two different areas of the primary tumour, and one 
FFPE sample was obtained from the lymph node metastasis. FFPE samples were cut (10 sections of 10 
µm each) for needle macrodissection using the stereo microscope Leica EZ4 (Leica Microsystems, Wetzlar, 
Germany) before RNA extraction in order to isolate the target cell populations (tumour or normal). A lung 
pathologist marked the tumour or normal areas on H&E-stained tissue sections. In addition, an RNA pool 
of 9 histologically normal lung tissues was used as a reference to calculate the relative miRNA expression. 
Therefore, we generated miRNA profiles using the following samples: tumour (N=2 fragments) and lymph 
node metastasis (N=1) from the same patient, and histologically normal lung tissues (N=9) as a reference. 
Considering that distinct areas of a tumour sample may have intratumoral heterogeneity, we analysed 
miRNA expression in the two tumour fragments, independently, and confirmed that they were homogeneous 
regarding their global miRNA expression levels.
RNA extraction
RNA was extracted using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE tissues (Ambion/
Thermo Fisher), according to the manufacturer’s instructions.
miRNA expression analysis
TaqMan Array Human microRNA card A v.3.0 (Life Technologies/Thermo Fisher Scientific) was used 
to identify commonly deregulated miRNAs in tumour and metastasis based on a panel of 384 miRNAs, 
including controls, as previously reported [15]. Our raw, original data are fully available on Gene Expression 
Omnibus (GEO) under the accession number GSE138708.
Cell Physiol Biochem 2021;55(S2):1-12
DOI: 10.33594/000000320
Published online: 6 January 2021 4
Cellular Physiology 
and Biochemistry
© 2021 The Author(s). Published by 
Cell Physiol Biochem Press GmbH&Co. KG
Seneda et al.: MicroRNAs as Regulators of Adaptive Immunity in Metastatic Lung 
Carcinoids
Computational analyses
miRNA target genes were predicted using the updated version of miRTaRBase, in order to identify 
experimentally-validated miRNA-target gene interactions [16] (date of access: Sept 22, 2020). miRNA-
mRNA networks were also generated using the miRNet 2.0 (https://www.mirnet.ca/miRNet/home.xhtml), 
a useful platform that allows integrating experimental data with existing literature datasets and scientific 
knowledge on interaction networks [17]. In addition, ToppGene Suite (https://toppgene.cchmc.org/) [18] 
(date of access: Sept 22, 2020) was used to identify statistically enriched pathways and gene ontologies 
(GO). A Venn diagram was generated using jvenn viewer (http://jvenn.toulouse.inra.fr/app/example.html) 
[19].
Validation of miRNA and target gene expression in external datasets
In order to validate miRNAs identified in our study, using independent datasets, we retrieved publicly 
available miRNA expression data from the Gene Expression Omnibus (GEO) [20]. We searched for publicly 
available datasets using the following inclusion criteria: original raw data available, on global miRNA 
expression generated in primary typical human lung carcinoids, including non-metastatic and metastatic 
cases, and with data on histologically normal lung tissues for comparison. Based on these inclusion criteria, 
one dataset (GSE77380) [14] was selected and included for validation. The GSE77380 dataset included two 
metastatic cases, and the platform of analysis was the Agilent Human_miRNA_V16.0_Microarray. miRNA 
expression levels were determined by comparing typical carcinoids (N=19) and normal tissues (N=6). An 
additional analysis was performed and included the two metastatic cases only.
In order to provide evidence of gene expression deregulation in typical lung carcinoids, target gene 
(mRNA) expression was validated using the GSE35679 dataset [21], which included 13 lung carcinoid 
samples (six typical and seven atypical tumours). We selected this dataset since the raw data was fully 
available for download and analysis, and the authors included only surgically resected primary tumours 
from treatment naïve patients. Raw miRNA or target gene expression data were analysed using the same 
bioinformatics tool, GEO2R [20] with its default parameters.
Statistical analysis
miRNA expression profiles were generated using ExpressionSuite software (Applied Biosystems/
Thermo Fisher Scientific), based on the Delta Delta Ct method of analysis [22]. A global normalization 
strategy was applied using stable endogenous controls included in the TaqMan assay. Statistical analyses 
used the Benjamini & Hochberg false discovery rate (FDR) method to determine corrected p-values [23] in 
all datasets: TaqMan miRNA expression analysis in tumour and metastasis vs. normal, and in the external 
validation datasets (miRNA, GSE77380 and target gene expression, GSE35679).
Results
Tissue samples exhibited histological features and biomarkers characteristic of a typical 
carcinoid tumour
Histological analysis of surgically resected tumour and lymph nodes showed tumour 
cells having nuclei with small to intermediate size and heterogeneous chromatin. The 
tumour stroma was vascularized. There was one mitotic cell in 10 large magnification 
fields. No angiolymphatic or perineural invasion or necrosis was observed. The Ki-67 
proliferation index was 1%. Histopathological features of this typical carcinoid tumour 
are shown in Fig. 1A; neuroendocrine differentiation is shown by immunopositivity of 
chromogranin and synaptophysin [2] (Fig. 1B and 1C). One of the three resected lymph 
nodes showed cytomorphological aspects identical to the tumour. Immunohistochemical 
biomarker analysis of this lymph node sample confirmed epithelial histogenesis of tumour 
cells, showing immunopositivity to cytokeratins (AE1/AE3) (Fig. 1D). Immunopositivity for 
chromogranin and synaptophysin confirmed the diagnosis of a typical lung carcinoid tumour 
with metastasis lesions in 1/3 lymph nodes.
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A subset of miRNAs is commonly deregulated in tumour and its corresponding lymph node 
metastasis
28 miRNAs were significantly deregulated (21 downregulated and 7 upregulated) 
(FC≥2 and p<0.05) in the two fragments of the tumour and 40 (38 down and 2 upregulated) 
in the metastatic sample. Global miRNA expression profiles were highly correlated in the two 
tumour areas (r=0.97, Pearson correlation) demonstrating that the two tumour fragments 
were homogeneous regarding their miRNA expression levels.
We were able to identify 17 commonly deregulated miRNAs (FC≥2 and p<0.05), with 
most miRNAs (15) being downregulated, one miRNA (miR-411-5p) was upregulated and 
one miRNA (miR-191-5p) showed opposite expression levels (upregulated in tumour 
and downregulated in metastasis) (Supplementary Table 1, Fig. 2 – for all supplementary 
material see www.cellphysiolbiochem.com). Of the downregulated miRNAs, 12 exhibited a 
notable further decrease in expression in the metastasis compared to the primary tumour 
(Table 1).
miRNA target genes are known to regulate pathways of adaptive immune response
miRTaRBase target prediction analysis [16] was performed using the commonly 
deregulated miRNAs in tumour and metastasis. Prediction analysis showed 485 unique gene 
targets with experimental evidence, provided by different methods including luciferase 
reporter assay, immunoblotting and others (Supplementary Table 2). Genes were further 
mapped on 15 significantly (p<0.01) enriched pathways including at least 500 genes in each 
annotation. Among the pathways identified, 59 genes were involved in adaptive immune 
response and 61 genes encoding extracellular matrix and extracellular matrix-associated 
Fig. 1. (A) Haematoxylin and Eosin (H&E) stained section of the low grade, typical carcinoid tumour of 
the lung. Chromatin in cell nuclei show evident “salt and pepper” patterning as indicated by black arrows. 
Tumour shows characteristic organoid tumour growth with vascularization (indicated by black stars *) and 
absence of necrosis and lack of mitotic activity, 400X magnification. (B) Immunohistochemical stained sec-
tion showing positivity for synaptophysin, a specific biomarker expressed in the typical subtype of carcinoid 
tumours, 400X magnification. (C) Immunohistochemical stained section showing positivity for chromogra-
nin A, 200X magnification. (D) Immunohistochemical stained section showing positivity for cytokeratins 
(AE1/AE3), 200X magnification. The green stars* indicate positive immune staining areas.
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proteins, which have known roles related to invasion 
and metastasis (Supplementary Table 3). Interaction 
networks identified were significantly (p<0.05) 
enriched by deregulated miRNAs and genes that play 
roles in adaptive immune response (Supplementary 
Fig. 1).
Downregulation of miR-126-3p and miR-146b-5p 
was validated in an independent, external miRNA 
expression dataset
When we compared our miRNA data with 
the GSE77380 dataset [14], we found that two 
miRNAs identified in our results were validated as 
significantly under-expressed: miR-126-3p and miR-
146b-5p  (Table 2).
Overexpression of SOX2 and TCF4 genes, targeted 
by miR-126-3p, was verified in typical carcinoid 
tumours from an independent, external gene 
expression dataset
The GSE35679 dataset [21] was used for 
validation of deregulated gene expression in lung 
typical (n=6) versus atypical (n=7) carcinoids. This 
dataset did not include histologically normal samples 
for comparative analysis. Results showed a total of 
28 deregulated genes targeted by the deregulated miRNAs identified in the TaqMan array 
analysis. Supplementary Table 4 shows the expression of the 28 genes in typical vs. atypical 
tumours, and corresponding miRNAs. The expression of all genes and miRNAs was inversely 
correlated (miRNAs downregulated/genes upregulated, and vice-versa).
We were thus able to validate over-expression of SOX2 and TCF4 genes, directly targeted 
by miR-126-3p, in typical lung carcinoids (Table 3). TCF4 was identified as included in 2/15 
(13%) pathways and in 44/437 (10%) of gene ontology annotations. SOX2 appeared in a larger 
dataset of significant (p<0.01) results, being identified in 4/15 (26%) of significant (p<0.01) 
Table 1. Commonly deregulated miRNAs in typical 
carcinoid tumour and metastasis. FC: fold change 
(log10 values). Corrected p-values were determined 
by the Benjamini Hochberg method
 
Fig. 2. Venn diagram depicting the number of de-
regulated miRNAs commonly deregulated and ex-
clusive to tumour and metastasis.
Table 2. Validated miRNAs in the external 
dataset GSE77380 [14]. FC: fold change 
(log10 values). *Corrected p-values were 
determined by the Benjamini Hochberg 
method
 
Table 3. Expression levels of SOX2 and 
TCF4 in a separate subset of typical (n=6) 
vs. atypical (n=7) lung carcinoids. Results 
were derived from GEO2R [20] analysis 
of the dataset GSE35679 [21]. Note that 
SOX2 over-expression was detected by 
two different probes in the Affymetrix 
array platform (U133 Plus 2.0) used for 
gene expression analysis. *Corrected p-
values: Benjamini Hochberg method
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pathways and in 110/437 (25%) of gene ontology annotations (GO). Supplementary Table 3 
shows the enriched pathways and GO annotations. miR-126-3p (miRNA-mRNA network) is 
shown in Fig. 3. A putative model of miRNA-modulated pathways associated with carcinoid 
progression is illustrated in Fig. 4.
Fig. 4. The 16 commonly altered miRNAs in primary tumour and lymph node metastasis regulate the ex-
pression of genes involved in immune response, cellular proliferation, and extracellular matrix remodelling, 
related to invasion and metastatic potential. A subset of 12 miRNAs was further downregulated in metasta-
sis, suggesting a potential role for deregulated miRNA-mRNA networks in disease progression. This figure 
was generated using BioRender.com.
Fig. 3. miRNA-mRNA interac-
tion network showing miR-126-
3p regulated targets, highlighting 
SOX2 and TCF4 genes, which had 
increased expression validated in 
typical lung carcinoids (external 
dataset GSE35679). Genes showed 
in this network are expressed in 
lung tissue. Network was built us-
ing miRNet web-based interaction 
tool [17].
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Discussion
Lung typical carcinoids are not commonly observed, and the presence of lymph node 
metastasis is reported in about 9% of cases [4]. The case presented here matches the 
classification criteria for typical carcinoid tumours, with less than 2 mitoses per 2 mm² 
and the absence of necrosis [2]. Interestingly, digestive neuroendocrine cancers are highly 
vascularized, with well-differentiated tumours having a higher microvessel density compared 
to poorly differentiated cases [24]. This characteristic of neuroendocrine cancers, associated 
with the acquisition of molecular changes, may explain disease progression with metastatic 
spread observed in some typical, well-differentiated lung carcinoid tumours.
Lung carcinoids have a low frequency of mutations [7]. The underlying molecular 
mechanisms of carcinoid tumorigenesis may include deregulation of miRNAs, which are 
potent gene expression modulators. Here, we were able to identify miRNAs as potential 
drivers of disease progression, by analysing tumour and metastasis from the same patient.
Importantly, we identified that a subset of miRNAs was commonly downregulated in 
tumour and lymph node metastasis with marked further decreased expression levels in 
metastasis compared to the primary tumour. Our results are comparable to previous studies 
that also identified miRNA underexpression in typical and atypical lung carcinoids with 
lymph node metastasis [13, 14]. Altogether, these data suggest that miRNAs may have a 
tumour suppressive role with downregulated levels associated with disease progression. 
Our main findings agree with current evidence showing that metastatic progression 
accumulates further changes compared to the primary tumour (28 miRNAs deregulated 
in tumour and 40 miRNAs deregulated in metastasis, with 17 in common being 16 with 
decreased levels in paired lymph node metastasis). Our data support existing evidence on 
metastatic dissemination upon immune system modulation by identifying candidate miRNAs 
that play important regulatory roles in immunoregulatory responses including the adaptive 
immunity [25].
The 16 commonly deregulated miRNAs in tumour and regional metastasis directly target 
carcinogenesis-associated genes, a finding that is consistent with their tumour suppressive 
effect. Five out of 16 identified miRNAs (let-7e-5p, miR-186-5p, miR-24-3p, miR-29a-3p, and 
miR-411-5p) have been previously reported in a comparison between typical vs. atypical 
lung carcinoids [13].
Although our study included the analysis of only one patient, we validated our miRNA 
and gene expression results in previously published datasets. To the best of our knowledge, 
among published studies reporting large-scale microRNA data on lung carcinoids [11–14], 
two studies included metastatic typical lung carcinoid cases [13, 14]. We were able to obtain 
raw data from Yoshimoto et al. (GSE77380) [14], and validated downregulation of miR-126-
3p and miR-146b-5p in typical metastatic carcinoids. Interestingly, our miRNA profiling 
results were more consistent with the metastatic cases, rather than the entire patient set 
including non-metastatic cases. These results corroborate the putative role of identified 
miRNAs in carcinoid tumour metastatic phenotype. To date, miR-126-3p underexpression 
has been identified in lung adenocarcinoma tissues, and able to predict pathological stage, 
tumour size, and the presence of lymph node metastasis [26]. The study by Rapa et al. [27] 
reported high expression of ACVR2B correlated with aggressive carcinoid tumour features. 
Interestingly, this gene is a predicted target of miR-126-3p.
In NSCLC, lower miR-146b-5p expression was associated with decreased survival and 
negatively correlated with TRAF6 (TNF receptor-associated factor-6). In addition, miR-146b-
5p overexpression in NSCLC cells triggered cell cycle arrest at the G1 phase, and reduced cell 
proliferation, migration and invasion [28].
Our study showed an enrichment of miRNA target genes with roles in adaptive 
immune response, including PTEN, TRAF6, TLR4, IKBKG, NFKBIA, SOX2 and TCF4. Reduced 
PTEN expression has been shown able to increase the production of immunosuppressive 
cytokines, and to reduce T cell recruitment to the tumour microenvironment to lessen cell 
death mediated by T cells [29]. TRAF6 mediates TNF receptor superfamily and Interleukin 1 
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receptor signalling, playing a central role in NF-kB activation [30]. PTEN, TRAF6 and NFKB 
among other immune-related genes were included in the enriched pathways identified in 
our analysis.
Notably, both SOX2 and TCF4 play roles associated with adaptive immunity. Transcription 
factor 4 (TCF4) is expressed and controls differentiation of plasmacytoid dendritic cells, which 
are an important component of adaptive immunity [31, 32]. SOX2 encodes a transcription 
factor important to pluripotency of embryonic stem cells; it has an important role in lung 
development [33–35] and has high expression levels in lung cancer including neuroendocrine 
tumours [36]. SOX2 is a tumour-associated antigen in lung squamous cell carcinoma and 
adenocarcinoma with a potential role as a biomarker to stratify patients who may benefit 
from anti-PD-1 checkpoint inhibitors [37]. Importantly, Pyfferoen et al. reported a tumour-
infiltrating dendritic cell (TIDC) miRNA signature with negative prognostic impact in NSCLC. 
Notably, among the identified miRNAs, miR-126-3p was downregulated in TIDCs [38] 
suggesting a regulatory role of this miRNA in the tumour microenvironment.
A limitation of our study is the inclusion of samples from one patient only. Regarding to 
biological sample source, fresh frozen tissues in general show a better quality, and if possible 
may not be replaced by FFPE tissues. Although, FFPE tissues are a valuable sample source 
and a realistic substitute when fresh frozen tissues are unavailable, being useful for molecular 
analysis in the research and clinical settings [39]. Here, miRNA profiles were generated using 
FFPE samples. Notwithstanding, the platform of choice (TaqMan® arrays) contains probes 
optimized and suitable for robust and reproducible amplification of miRNAs using FFPE-
derived RNA. An additional limitation is the lack of gene expression validation in the same 
patient samples, due to the unavailability of tissues or RNA for additional analysis. However, 
we were able to verify increased mRNA levels of SOX2 and TCF4, which are targeted by the 
downregulated miR-126-3p, in typical carcinoids from an external dataset GSE35679 [21]. 
Interestingly, both TCF4 and SOX2 were included in enriched pathways and gene ontology 
annotations associated with immune response. Altogether, our results contribute to a better 
understanding of metastatic typical lung carcinoid biology.
miRNAs miR-126-3p and miR-146b-5p are commonly underexpressed in a typical lung 
carcinoid tumour and its lymph node metastasis. The identified miRNAs and target genes 
are useful to conduct future validation studies, necessary to implicate these molecules in the 
tumorigenesis and progression of these rare tumours.
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